Results 221 to 230 of about 23,034 (262)

Dynorphin Agonist Therapy of Parkinsonʼs Disease

Clinical Neuropharmacology, 1993
Striatal dynorphin system function may be altered in Parkinson's disease. To evaluate whether treatment with a selective dynorphin agonist improves motor symptoms, four parkinsonian patients received single daily injections of spiradoline under controlled conditions. Doses ranging from 1 to 4 micrograms/kg had no discernible effect on motor performance
M, Giuffra, M M, Mouradian, T L, Davis, J, Ownby, T N, Chase   +4 more
openaire   +2 more sources

Dynorphin receptor in the blood vessel

Neuropeptides, 1985
Using (3H)etorphine, (3H)E, in binding studies, the KD and Bmax for rabbit mesentery and aorta membrane preparations were 0.61 nM and 0.17 fmol/mg tissue respectively, while it was 0.30 nM and 12 fmol/mg tissue in the brain. The IC50 of dynorphin (1-13) (D1-13) for displacing (3H)E binding in the blood vessel was 20 +/- 2.8 nM (S,E,M,), while PLO17, D ...
F Y, Sun, A Z, Zhang
openaire   +2 more sources

Dynorphin peptides in human substantia nigra

Neuropeptides, 1985
Stepwise processing of the prohormone for dynorphin-related peptides, proenkephalin B, may generate a large number of opioid peptides. It is therefore important to perform a chemical characterization of the immunoreactive dynorphin (ir-dyn) found in different tissues. In this study dynorphin peptides in human substantia nigra were characterized. Highly
I, Christensson-Nylander, L, Terenius
openaire   +2 more sources

Epilepsy, CNS viral injury and dynorphin

Trends in Pharmacological Sciences, 2004
Epilepsy is a significant health problem. Despite the widespread use of both classic and newer pharmacological agents that target ion channels, amino acid transmission or receptors, there are numerous examples of mono- or polytherapy being ineffective.
Marylou V, Solbrig, George F, Koob
openaire   +2 more sources

Dynorphins other than dynorphin A(1-17) lack spinal antianalgesic activity but do act on dynorphin A(1-17) receptors.

The Journal of Pharmacology and Experimental Therapeutics, 1991
In recent publications we have proposed that dynorphin (Dyn) A(1-17) functions as an antianalgesic modulator to oppose opioid-induced antinociception in mice. In the present experiments using the tail-flick response in mice, other Dyns [Dyn A(1-8), Dyn A(1-13), Dyn A(2-17), Dyn B and alpha- and beta-neoendorphin] when administered intrathecally (i.t ...
J J, Rady, J M, Fujimoto, L F, Tseng
openaire   +2 more sources

Neuropeptide processing by single-step cleavage: Conversion of leumorphin (dynorphin B-29) to dynorphin B

Biochemical and Biophysical Research Communications, 1985
Dynorphin B (rimorphin) is formed from dynorphin B-29 (leumorphin) by the action of a thiol protease from rat brain membranes. This represents a "single-arginine cleavage" between threonine-13 and arginine-14 of the substrate. In isotope dilution experiments we find that the radioactivity from radiolabelled dynorphin B-29, which appears in dynorphin B ...
L, Devi, A, Goldstein
openaire   +2 more sources

Dynorphins

2013
C. Renn Upchurch Sweeney, J. Rick Turner, J. Rick Turner, Chad Barrett, Ana Victoria Soto, William Whang, Carolyn Korbel, Sonia Matwin, Daniel Gorrin, Beth Schroeder, J. Rick Turner, Joost Dekker, Bonnie Levin, J. Rick Turner, Alefiyah Z. Pishori, John Grabowski, Samantha Yard, Kimberly Nelson, Ellen-ge Denton, Tatsuo Akechi, Monica Dowling, Brigitte M. Kudielka, Francine Kaufman, Luigi Meneghini, Luigi Meneghini, Kathleen Michael, David G. Marrero, Maartje de Wit, Jenny T. Wang, Jason S. Yeh, Janine Sanchez, J. Rick Turner, C. Renn Upchurch Sweeney, Annie T. Ginty, Kristen Salomon, Alvin Jin, Joel E. Dimsdale, Diane Dixon, Marijke Couck, Pamela S. King, Yori Gidron, Yori Gidron, Harry Prapavessis, Steven Gambert, Steven Gambert, J. Rick Turner, Lauren Zagorski, Wynne E. Norton, Kevin S. Masters, Lara Traeger, Nicole Brandt, Rachel Flurie, Brant P. Hasler, C. Andres Bedoya, Tamara Goldman Sher, Kathryn Noth, Jennifer Wessel, Edward L. Perkins, Howard Sollins, Debra Roter, Judith A. Hall, Laura Rodriguez-Murillo, Rany M. Salem, Michela Marinelli, Nicole Brandt, J. Rick Turner, Nicole Brandt, Faith S. Luyster, Ronald Goldberg, Valerie Sabol, Nina Rieckmann   +70 more
openaire   +2 more sources

Dynorphin immunoreactivity in pituitary.

Advances in biochemical psychopharmacology, 1982
Tissue ir-dynorphin has been shown to be associated with three components separable by gel filtration. Similar components were found in both pituitary and brain, although there are differences in the relative amounts of each component in each tissue.
B M, Cox, E R, Baer, A, Goldstein
openaire   +1 more source

Dynorphin/Kappa Opioid Receptor Signaling in Preclinical Models of Alcohol, Drug, and Food Addiction.

International review of neurobiology, 2017
Anushree N. Karkhanis, Katherine M. Holleran, S. Jones   +2 more
semanticscholar   +1 more source

Modulation of 5-HT release by dynorphin mediates social deficits during opioid withdrawal

Neuron, 2022
Robert C Malenka
exaly